Arcturus Therapeutics Holdings Management
Management criteria checks 2/4
Arcturus Therapeutics Holdings' CEO is Joe Payne, appointed in Mar 2013, has a tenure of 11.08 years. total yearly compensation is $5.59M, comprised of 11.3% salary and 88.7% bonuses, including company stock and options. directly owns 5.5% of the company’s shares, worth $44.60M. The average tenure of the management team and the board of directors is 3.7 years and 5.3 years respectively.
Key information
Joe Payne
Chief executive officer
US$5.6m
Total compensation
CEO salary percentage | 11.3% |
CEO tenure | 11.1yrs |
CEO ownership | 5.5% |
Management average tenure | 3.7yrs |
Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Apr 09Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking
Feb 06Arcturus: H1 2024 Rare Disease Drug Data On Deck
Jan 31Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?
Jan 11Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?
Dec 14Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business
Sep 14Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 08Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Jul 19Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher
May 18Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet
May 02Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money
Dec 28Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 23Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine
Aug 31Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)
Aug 15Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks
Aug 10Arcturus: Potential Based On Rare Disease Therapy ARCT-810
Jun 07These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat
May 11Arcturus: Biotech With Great Potential In Covid-19 Vaccine Space
Apr 25Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load?
Jan 22Arcturus: Emerging Covid Variants May Provide A Raison D'êTre
Nov 28CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$30m |
Sep 30 2023 | n/a | n/a | US$99m |
Jun 30 2023 | n/a | n/a | US$80m |
Mar 31 2023 | n/a | n/a | US$111m |
Dec 31 2022 | US$6m | US$630k | US$9m |
Sep 30 2022 | n/a | n/a | -US$147m |
Jun 30 2022 | n/a | n/a | -US$165m |
Mar 31 2022 | n/a | n/a | -US$198m |
Dec 31 2021 | US$960k | US$600k | -US$204m |
Sep 30 2021 | n/a | n/a | -US$196m |
Jun 30 2021 | n/a | n/a | -US$163m |
Mar 31 2021 | n/a | n/a | -US$119m |
Dec 31 2020 | US$13m | US$500k | -US$72m |
Sep 30 2020 | n/a | n/a | -US$52m |
Jun 30 2020 | n/a | n/a | -US$38m |
Mar 31 2020 | n/a | n/a | -US$29m |
Dec 31 2019 | US$1m | US$450k | -US$26m |
Sep 30 2019 | n/a | n/a | -US$16m |
Jun 30 2019 | n/a | n/a | -US$13m |
Mar 31 2019 | n/a | n/a | -US$22m |
Dec 31 2018 | US$3m | US$425k | -US$22m |
Sep 30 2018 | n/a | n/a | -US$26m |
Jun 30 2018 | n/a | n/a | -US$25m |
Mar 31 2018 | n/a | n/a | -US$16m |
Dec 31 2017 | US$449k | US$384k | -US$11m |
Compensation vs Market: Joe's total compensation ($USD5.59M) is above average for companies of similar size in the US market ($USD3.45M).
Compensation vs Earnings: Joe's compensation has increased whilst the company is unprofitable.
CEO
Joe Payne (51 yo)
11.1yrs
Tenure
US$5,594,000
Compensation
Mr. Joseph E. Payne, also known as Joe, M.Sc. has been Independent Non-Executive Director of Vallon Pharmaceuticals, Inc. since June 22, 2018. Mr. Payne has been Director of Arcturus since November 2017. H...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder | 11.1yrs | US$5.59m | 5.5% $ 44.6m | |
Founder | 11.3yrs | US$3.11m | 1.76% $ 14.3m | |
CFO & Director | 5.7yrs | US$3.15m | 1.01% $ 8.2m | |
Vice President and Head of IR/PR & Marketing | no data | no data | no data | |
Chief Legal Officer | 3.7yrs | US$560.00k | no data | |
Chief Human Resources Officer | less than a year | no data | no data | |
Chief Business Officer | 5.6yrs | no data | no data | |
Chief Medical Officer | less than a year | no data | no data | |
Chief Development Officer | less than a year | no data | no data | |
Controller | less than a year | no data | no data |
3.7yrs
Average Tenure
55yo
Average Age
Experienced Management: ARCT's management team is considered experienced (3.7 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder | 11.1yrs | US$5.59m | 5.5% $ 44.6m | |
CFO & Director | 4.6yrs | US$3.15m | 1.01% $ 8.2m | |
Independent Chairman of the Board | 5.9yrs | US$305.30k | 0.36% $ 2.9m | |
Independent Director | 4.6yrs | US$293.35k | 0% $ 0 | |
Independent Director | 5.9yrs | US$302.80k | 0.037% $ 301.3k | |
Independent Director | 5.9yrs | US$292.80k | 0.093% $ 751.5k | |
Member of the Vaccine Platform Scientific Advisory Board | 3.8yrs | no data | no data | |
Member of Scientific Advisory Board | 9.3yrs | no data | no data | |
Member of Scientific Advisory Board | 8.4yrs | no data | no data | |
Member of the Vaccine Platform Scientific Advisory Board | 3.8yrs | no data | no data | |
Strategic Clinical Advisor & Member of Scientific Advisory Board | 2.1yrs | US$644.00k | no data | |
Member of the Vaccine Platform Scientific Advisory Board | 3.8yrs | no data | no data |
5.3yrs
Average Tenure
64yo
Average Age
Experienced Board: ARCT's board of directors are considered experienced (5.3 years average tenure).